Shilpa Medicare Telangana facility gets Health Canada GMP approval

1 Dec 2022 , 09:16 AM

Shilpa Medicare Ltd’s finished dosage form manufacturing facility, Unit IV, situated at Pharma SEZ, Jadcherla, Telangana has received Health Canada GMP approval for the inspection conducted from September 12, 2022 to September 16, 2022.

The facility is involved in manufacturing, packaging, labelling and testing of finished dosage forms (sterile injections and oral solids) for the treatment of cancer and adjuvant therapy.

This GMP approval will allow the company for the commercial distribution of products in Canada and enable new application submissions to Health Canada.

This approval reaffirms the company’s focused efforts to maintain the GMP status up to the standards of global regulatory authorities.

At around 9:17 AM, Shilpa Medicare Ltd is currently trading at Rs300.85 per share up by Rs19.3 or 6.85% from its previous closing of Rs281.55 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]